Literature DB >> 33051603

Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.

Changyu Zhu1,2, Ira Tabas1, Robert F Schwabe1, Utpal B Pajvani3.   

Abstract

With the rapid expansion of the obesity epidemic, nonalcoholic fatty liver disease is now the most common chronic liver disease, with almost 25% global prevalence. Nonalcoholic fatty liver disease ranges in severity from simple steatosis, a benign 'pre-disease' state, to the liver injury and inflammation that characterize nonalcoholic steatohepatitis (NASH), which in turn predisposes individuals to liver fibrosis. Fibrosis is the major determinant of clinical outcomes in patients with NASH and is associated with increased risks of cirrhosis and hepatocellular carcinoma. NASH has no approved therapies, and liver fibrosis shows poor response to existing pharmacotherapy, in part due to an incomplete understanding of the underlying pathophysiology. Patient and mouse data have shown that NASH is associated with the activation of developmental pathways: Notch, Hedgehog and Hippo-YAP-TAZ. Although these evolutionarily conserved fundamental signals are known to determine liver morphogenesis during development, new data have shown a coordinated and causal role for these pathways in the liver injury response, which becomes maladaptive during obesity-associated chronic liver disease. In this Review, we discuss the aetiology of this reactivation of developmental pathways and review the cell-autonomous and cell-non-autonomous mechanisms by which developmental pathways influence disease progression. Finally, we discuss the potential prognostic and therapeutic implications of these data for NASH and liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33051603      PMCID: PMC7854502          DOI: 10.1038/s41575-020-00365-6

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  167 in total

1.  Obesity and diabetes in the developing world--a growing challenge.

Authors:  Parvez Hossain; Bisher Kawar; Meguid El Nahas
Journal:  N Engl J Med       Date:  2007-01-18       Impact factor: 91.245

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 3.  Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.

Authors:  Ana Ruth Araújo; Natalia Rosso; Giorgio Bedogni; Claudio Tiribelli; Stefano Bellentani
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

4.  Reply.

Authors:  Maria Stepanova; Zobair Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2020-11-26       Impact factor: 11.382

Review 5.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

Review 6.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 7.  The epidemiology of nonalcoholic fatty liver disease: a global perspective.

Authors:  Mariana Lazo; Jeanne M Clark
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 8.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

9.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.

Authors:  Donghee Kim; W Ray Kim; Hwa Jung Kim; Terry M Therneau
Journal:  Hepatology       Date:  2013-01-25       Impact factor: 17.425

Review 10.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

View more
  19 in total

Review 1.  Metabolic liver disease - what's in a name?

Authors:  Mark A Herman
Journal:  Nat Rev Endocrinol       Date:  2021-02       Impact factor: 43.330

2.  Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Authors:  Z Wang; Z Zhao; Y Xia; Z Cai; C Wang; Y Shen; R Liu; H Qin; J Jia; G Yuan
Journal:  J Endocrinol Invest       Date:  2022-02-28       Impact factor: 4.256

3.  14-3-3ζ inhibits maladaptive repair in renal tubules by regulating YAP and reduces renal interstitial fibrosis.

Authors:  Tian-Tian Wang; Ling-Ling Wu; Jie Wu; Li-Sheng Zhang; Wan-Jun Shen; Ying-Hua Zhao; Jiao-Na Liu; Bo Fu; Xu Wang; Qing-Gang Li; Xue-Yuan Bai; Li-Qiang Wang; Xiang-Mei Chen
Journal:  Acta Pharmacol Sin       Date:  2022-07-15       Impact factor: 7.169

4.  MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.

Authors:  Hong Gao; Zhongmou Jin; Gautam Bandyopadhyay; Karina Cunha E Rocha; Xiao Liu; Huayi Zhao; Dinghong Zhang; Hani Jouihan; Soheil Pourshahian; Tatiana Kisseleva; David A Brenner; Wei Ying; Jerrold M Olefsky
Journal:  Cell Metab       Date:  2022-06-13       Impact factor: 31.373

Review 5.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

Review 6.  Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Authors:  Laura E Dichtel; Jose Cordoba-Chacon; Rhonda D Kineman
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

7.  Developmental programming: Metabolic tissue-specific changes in endoplasmic reticulum stress, mitochondrial oxidative and telomere length status induced by prenatal testosterone excess in the female sheep.

Authors:  Muraly Puttabyatappa; Joseph N Ciarelli; Adam G Chatoff; Vasantha Padmanabhan
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

8.  Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis.

Authors:  Jimin Kim; Seul Ki Lee; Seon-Yeong Jeong; Hye Jin Cho; Joonghoon Park; Tae Min Kim; Soo Kim
Journal:  J Nanobiotechnology       Date:  2021-11-17       Impact factor: 10.435

Review 9.  The Roles and Mechanisms of lncRNAs in Liver Fibrosis.

Authors:  Zhifa Wang; Xiaoke Yang; Siyu Gui; Fan Yang; Zhuo Cao; Rong Cheng; Xiaowei Xia; Chuanying Li
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

Review 10.  Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.

Authors:  Yi-Wen Shi; Rui-Xu Yang; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.